Skip to main content

Table 3 Comparing patients with MRONJ between MM stages according to each factor (sign, location, etiologic factor, BP type, treatment, and outcome) of MM

From: Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma

  Stage
1 2 3 P value
Number of patients 2 6 1  
Location (%)     1
 Mandible 2 (100) 5 (83.33) 1 (100)  
 Maxilla 0 (0) 1 (16.67) 0 (0)  
Infection (%)     0.0476*
 Yes 0 (0) 5 (83.33) 0 (0)  
 No 2 (100) 1 (16.67) 1 (100)  
Etiology (%)     0.7222
 Extraction 1 (50) 3 (50) 1 (100)  
 Prosthesis problem 0 (0) 2 (33.33) 0 (0)  
 Periodontal problem 0 (0) 1 (16.67) 0 (0)  
 Spontaneous 1 (50) 0 (0) 0 (0)  
Bisphosphonate type (%)     0.25
Combinationa 2 (100) 5 (83.33) 0 (0)  
 Only zoledronate 0 (0) 1 (16.67) 0 (0)  
 Only pamidronate 0 (0) 0 (0) 1 (100)  
Treatmentb (%)     0.6429
 Conservative 2 (100) 3 (50) 1 (100)  
 Invasive 0 (0) 3 (50) 0 (0)  
Outcome (%)     1
 1 1 (100) 4 (80) 0 (0)  
 2 0 (0) 1 (20) 0 (0)  
Duration in months 21 (17–25) 19 (11–69) 9 (9–9) 0.2992
  1. Categorical variables such as sign, location, etiologic factor, BP type, treatment, and outcome were analyzed by Fisher’s exact test. Continuous variables such as duration were analyzed by Wilcoxon test
  2. *Statistically significant (p value <0.05)
  3. aCombination of zoledronate and pamidronate
  4. bConservative: antibiotic therapy and dressing invasive: biopsy or saucerization